WO2005096784A2 - Benzotriazine inhibitors of kinases - Google Patents
Benzotriazine inhibitors of kinases Download PDFInfo
- Publication number
- WO2005096784A2 WO2005096784A2 PCT/US2005/012057 US2005012057W WO2005096784A2 WO 2005096784 A2 WO2005096784 A2 WO 2005096784A2 US 2005012057 W US2005012057 W US 2005012057W WO 2005096784 A2 WO2005096784 A2 WO 2005096784A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- mmol
- subject
- disorder
- methyl
- Prior art date
Links
- 0 *N1CCN(CCBr)CC1 Chemical compound *N1CCN(CCBr)CC1 0.000 description 13
- HUKKIICEYSQETK-UHFFFAOYSA-N Cc1cc(-c2cc(Cl)ccc2OC)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2 Chemical compound Cc1cc(-c2cc(Cl)ccc2OC)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2 HUKKIICEYSQETK-UHFFFAOYSA-N 0.000 description 2
- VAWLAPYBUJTXRS-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1S(C1CCNCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1S(C1CCNCC1)(=O)=O)nn2 VAWLAPYBUJTXRS-UHFFFAOYSA-N 0.000 description 2
- BOQLSYBMPFBUNE-UHFFFAOYSA-N Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 Chemical compound Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 BOQLSYBMPFBUNE-UHFFFAOYSA-N 0.000 description 2
- MVFMLKKYUBDPJB-ZRDIBKRKSA-N C/C(/Nc1nc(c(C)cc(-c2cc(O)ccc2Cl)c2)c2nn1)=C\N=C(/C)\NC(C)=O Chemical compound C/C(/Nc1nc(c(C)cc(-c2cc(O)ccc2Cl)c2)c2nn1)=C\N=C(/C)\NC(C)=O MVFMLKKYUBDPJB-ZRDIBKRKSA-N 0.000 description 1
- KDTFQAJYJIGSFS-UHFFFAOYSA-N CC(C)N(CCN1CCCC1)S(c(cc1)ccc1Nc1nc(c(C)cc(-c2cc(O)ccc2Cl)c2)c2nn1)(=O)=O Chemical compound CC(C)N(CCN1CCCC1)S(c(cc1)ccc1Nc1nc(c(C)cc(-c2cc(O)ccc2Cl)c2)c2nn1)(=O)=O KDTFQAJYJIGSFS-UHFFFAOYSA-N 0.000 description 1
- RPSBJRWUMIHPGU-UHFFFAOYSA-N CC(C1(C)N=C(N)N=NC1=C1)C=C1Br Chemical compound CC(C1(C)N=C(N)N=NC1=C1)C=C1Br RPSBJRWUMIHPGU-UHFFFAOYSA-N 0.000 description 1
- VLWSURYZZHVLKO-UHFFFAOYSA-N CC(Nc(nc1)ccc1Nc(nnc1c2)nc1c(C)cc2-c(cc(cc1)O)c1Cl)=O Chemical compound CC(Nc(nc1)ccc1Nc(nnc1c2)nc1c(C)cc2-c(cc(cc1)O)c1Cl)=O VLWSURYZZHVLKO-UHFFFAOYSA-N 0.000 description 1
- BCAHGWFHBBMPHP-UHFFFAOYSA-N CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2)=O Chemical compound CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2)=O BCAHGWFHBBMPHP-UHFFFAOYSA-N 0.000 description 1
- XAOYXVXFTLCFFS-UHFFFAOYSA-N CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1S(N(CCN1CCCC1)C(C)=O)(=O)=O)nn2)=O Chemical compound CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1S(N(CCN1CCCC1)C(C)=O)(=O)=O)nn2)=O XAOYXVXFTLCFFS-UHFFFAOYSA-N 0.000 description 1
- KGYCQGOAGCBPEB-UHFFFAOYSA-N CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2)=O Chemical compound CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2)=O KGYCQGOAGCBPEB-UHFFFAOYSA-N 0.000 description 1
- PFVCCMOOCGLRPV-ZBEWQZTPSA-O CC1(C)OB(/C(/C=[NH2+])=C/N)OC1(C)C Chemical compound CC1(C)OB(/C(/C=[NH2+])=C/N)OC1(C)C PFVCCMOOCGLRPV-ZBEWQZTPSA-O 0.000 description 1
- QRQCJOYHTJFZNZ-UHFFFAOYSA-N CC1C=C(C)C(c(cc2[N+]([O-])=O)cc([NH+]([N-]3)[O-])c2N=C3Nc(cc2)ccc2OCCN2CCCC2)=C(C)C1 Chemical compound CC1C=C(C)C(c(cc2[N+]([O-])=O)cc([NH+]([N-]3)[O-])c2N=C3Nc(cc2)ccc2OCCN2CCCC2)=C(C)C1 QRQCJOYHTJFZNZ-UHFFFAOYSA-N 0.000 description 1
- KJIBUWZGIDVJIY-UHFFFAOYSA-N CCCCc(cc1)ccc1Nc1nc(c(C)cc(-c2c(C)cccc2C)c2)c2nn1 Chemical compound CCCCc(cc1)ccc1Nc1nc(c(C)cc(-c2c(C)cccc2C)c2)c2nn1 KJIBUWZGIDVJIY-UHFFFAOYSA-N 0.000 description 1
- CNHISCQPKKGDPO-UHFFFAOYSA-N CCOC(c1c[s]c(Br)n1)=O Chemical compound CCOC(c1c[s]c(Br)n1)=O CNHISCQPKKGDPO-UHFFFAOYSA-N 0.000 description 1
- YVVBCSYTBZHHQG-UHFFFAOYSA-N CCOc(cc1)ccc1Nc1nc(c(C)cc(-c2cc(OC)cc(OC)c2)c2)c2nn1 Chemical compound CCOc(cc1)ccc1Nc1nc(c(C)cc(-c2cc(OC)cc(OC)c2)c2)c2nn1 YVVBCSYTBZHHQG-UHFFFAOYSA-N 0.000 description 1
- LXIIGQZZJVXONE-UHFFFAOYSA-N CCOc1cc2nc(N)nnc2cc1-c1ccccc1C Chemical compound CCOc1cc2nc(N)nnc2cc1-c1ccccc1C LXIIGQZZJVXONE-UHFFFAOYSA-N 0.000 description 1
- ITLNVPRPOQCABR-UHFFFAOYSA-N Cc(c(-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)nn2)c1)ccc1Cl Chemical compound Cc(c(-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)nn2)c1)ccc1Cl ITLNVPRPOQCABR-UHFFFAOYSA-N 0.000 description 1
- PWKWAGIBTGYEHC-UHFFFAOYSA-N Cc(c(-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2)c1)ccc1F Chemical compound Cc(c(-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2)c1)ccc1F PWKWAGIBTGYEHC-UHFFFAOYSA-N 0.000 description 1
- PHSGAESTNBYAHM-UHFFFAOYSA-N Cc(c(-c1cc(C)c2nc(Nc(cc3)ccc3S(NCCN3CCCC3)(=O)=O)nnc2c1)c1)ccc1O Chemical compound Cc(c(-c1cc(C)c2nc(Nc(cc3)ccc3S(NCCN3CCCC3)(=O)=O)nnc2c1)c1)ccc1O PHSGAESTNBYAHM-UHFFFAOYSA-N 0.000 description 1
- QPQTXSMCSCYFGQ-UHFFFAOYSA-N Cc(c(-c1cc(CO)ccc1)c1)cc2c1nnc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)n2 Chemical compound Cc(c(-c1cc(CO)ccc1)c1)cc2c1nnc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)n2 QPQTXSMCSCYFGQ-UHFFFAOYSA-N 0.000 description 1
- OUHRROUUMISCGY-UHFFFAOYSA-N Cc(c(-c1cc(O)ccc1)c1)cc2c1nnc(Nc(cc1)ccc1OCCN1CCCC1)n2 Chemical compound Cc(c(-c1cc(O)ccc1)c1)cc2c1nnc(Nc(cc1)ccc1OCCN1CCCC1)n2 OUHRROUUMISCGY-UHFFFAOYSA-N 0.000 description 1
- CPKWNMKGJMCCPZ-UHFFFAOYSA-N Cc(c(-c1cc(O)ccc1Cl)c1)cc2c1nnc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)n2 Chemical compound Cc(c(-c1cc(O)ccc1Cl)c1)cc2c1nnc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)n2 CPKWNMKGJMCCPZ-UHFFFAOYSA-N 0.000 description 1
- MVVFDSPVLRMEIA-UHFFFAOYSA-N Cc(c(-c1cc2nnc(Nc(cc3)ccc3OCCN3CCCC3)nc2cc1C)c1)ccc1O Chemical compound Cc(c(-c1cc2nnc(Nc(cc3)ccc3OCCN3CCCC3)nc2cc1C)c1)ccc1O MVVFDSPVLRMEIA-UHFFFAOYSA-N 0.000 description 1
- BPKCVPQTTDYEFX-UHFFFAOYSA-N Cc(c(Br)c1)cc2c1nnc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)n2 Chemical compound Cc(c(Br)c1)cc2c1nnc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)n2 BPKCVPQTTDYEFX-UHFFFAOYSA-N 0.000 description 1
- QOZSLSADUPZZKW-UHFFFAOYSA-N Cc(c(C)c1)ccc1Nc1nc(c(C)cc(-c2cc(OC)cc(OC)c2)c2)c2nn1 Chemical compound Cc(c(C)c1)ccc1Nc1nc(c(C)cc(-c2cc(OC)cc(OC)c2)c2)c2nn1 QOZSLSADUPZZKW-UHFFFAOYSA-N 0.000 description 1
- HUBLIJJKLJKNJL-UHFFFAOYSA-N Cc(cc1)ccc1Nc1nc(c(C)cc(-c2c(C)cccc2C)c2)c2nn1 Chemical compound Cc(cc1)ccc1Nc1nc(c(C)cc(-c2c(C)cccc2C)c2)c2nn1 HUBLIJJKLJKNJL-UHFFFAOYSA-N 0.000 description 1
- KDWPMSHIURZDIJ-UHFFFAOYSA-N Cc(cccc1C)c1-c(cc1C)cc2c1nc(Nc(cccc1)c1OC)nn2 Chemical compound Cc(cccc1C)c1-c(cc1C)cc2c1nc(Nc(cccc1)c1OC)nn2 KDWPMSHIURZDIJ-UHFFFAOYSA-N 0.000 description 1
- NGYGJKWFCRECQN-UHFFFAOYSA-N Cc1c2nc(Nc(cc3)ccc3S(N3CCN(C)CC3)(=O)=O)nnc2cc(-c2cc(O)ccc2Cl)c1 Chemical compound Cc1c2nc(Nc(cc3)ccc3S(N3CCN(C)CC3)(=O)=O)nnc2cc(-c2cc(O)ccc2Cl)c1 NGYGJKWFCRECQN-UHFFFAOYSA-N 0.000 description 1
- OLAQXRSNCGXDSZ-UHFFFAOYSA-N Cc1c2nc(Nc(cc3)cnc3OC)nnc2cc(-c2cc(O)ccc2Cl)c1 Chemical compound Cc1c2nc(Nc(cc3)cnc3OC)nnc2cc(-c2cc(O)ccc2Cl)c1 OLAQXRSNCGXDSZ-UHFFFAOYSA-N 0.000 description 1
- NZKIVHPJIICWNI-UHFFFAOYSA-N Cc1c2nc(Nc3cccc(S(N4CCN(C)CC4)(=O)=O)c3)nnc2cc(-c2cc(OC)ccc2Cl)c1 Chemical compound Cc1c2nc(Nc3cccc(S(N4CCN(C)CC4)(=O)=O)c3)nnc2cc(-c2cc(OC)ccc2Cl)c1 NZKIVHPJIICWNI-UHFFFAOYSA-N 0.000 description 1
- IKBJFCQBZQVKJN-UHFFFAOYSA-N Cc1c2nc(Nc3cccc(SCCN4CCCC4)c3)nnc2cc(-c2cc(OC)ccc2Cl)c1 Chemical compound Cc1c2nc(Nc3cccc(SCCN4CCCC4)c3)nnc2cc(-c2cc(OC)ccc2Cl)c1 IKBJFCQBZQVKJN-UHFFFAOYSA-N 0.000 description 1
- TUMITOMFWDJDDQ-UHFFFAOYSA-N Cc1cc(-c(c(Cl)ccc2)c2Cl)cc2c1nc(Nc(cc1)ccc1S(N(C)CCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c(c(Cl)ccc2)c2Cl)cc2c1nc(Nc(cc1)ccc1S(N(C)CCN1CCCC1)(=O)=O)nn2 TUMITOMFWDJDDQ-UHFFFAOYSA-N 0.000 description 1
- ODSUGJKWJKAXHT-UHFFFAOYSA-N Cc1cc(-c(c(Cl)ccc2)c2Cl)cc2c1nc(Nc1ccncc1)nn2 Chemical compound Cc1cc(-c(c(Cl)ccc2)c2Cl)cc2c1nc(Nc1ccncc1)nn2 ODSUGJKWJKAXHT-UHFFFAOYSA-N 0.000 description 1
- WQACVRFKZIYHIM-UHFFFAOYSA-N Cc1cc(-c(c(Cl)ccc2)c2O)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c(c(Cl)ccc2)c2O)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 WQACVRFKZIYHIM-UHFFFAOYSA-N 0.000 description 1
- RVVMRHQNWBCVAS-UHFFFAOYSA-N Cc1cc(-c(c(Cl)ccc2OC)c2F)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c(c(Cl)ccc2OC)c2F)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 RVVMRHQNWBCVAS-UHFFFAOYSA-N 0.000 description 1
- WGOCYFJXNFKHER-UHFFFAOYSA-N Cc1cc(-c(cc(cc2)O)c2Cl)cc2c1nc(N)nn2 Chemical compound Cc1cc(-c(cc(cc2)O)c2Cl)cc2c1nc(N)nn2 WGOCYFJXNFKHER-UHFFFAOYSA-N 0.000 description 1
- VTSREOCPHUZXLM-UHFFFAOYSA-N Cc1cc(-c2cc(NS(C)(=O)=O)ccc2)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c2cc(NS(C)(=O)=O)ccc2)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 VTSREOCPHUZXLM-UHFFFAOYSA-N 0.000 description 1
- PFAJPANEBVTDTK-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(NCCCCN1CCCC1)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(NCCCCN1CCCC1)nn2 PFAJPANEBVTDTK-UHFFFAOYSA-N 0.000 description 1
- NMSHJWKGPWRUSI-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1C(N(CC1)CCS1(=O)=O)=O)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1C(N(CC1)CCS1(=O)=O)=O)nn2 NMSHJWKGPWRUSI-UHFFFAOYSA-N 0.000 description 1
- NXTAONONNMIHOO-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1S(N(C)CCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1S(N(C)CCN1CCCC1)(=O)=O)nn2 NXTAONONNMIHOO-UHFFFAOYSA-N 0.000 description 1
- MZDZFBRVVPRKIT-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1cc(N(C)C)ccc1)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1cc(N(C)C)ccc1)nn2 MZDZFBRVVPRKIT-UHFFFAOYSA-N 0.000 description 1
- RIBZJJDUKXDJMG-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1cccc(OCCN3CCCC3)c1)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1cccc(OCCN3CCCC3)c1)nn2 RIBZJJDUKXDJMG-UHFFFAOYSA-N 0.000 description 1
- NYABGVVHNWYTPF-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 NYABGVVHNWYTPF-UHFFFAOYSA-N 0.000 description 1
- GFXCTQSIXXAOBE-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3cccc(S(NCCN(C)C)(=O)=O)c3)nc12 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3cccc(S(NCCN(C)C)(=O)=O)c3)nc12 GFXCTQSIXXAOBE-UHFFFAOYSA-N 0.000 description 1
- XWNOQCSTHKPRDW-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2[ClH]C)cc2c1nc(NC(C=C1)=CN(C)C1C(NCCN1CCCC1)=O)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2[ClH]C)cc2c1nc(NC(C=C1)=CN(C)C1C(NCCN1CCCC1)=O)nn2 XWNOQCSTHKPRDW-UHFFFAOYSA-N 0.000 description 1
- JFPQJONXEVRXFI-UHFFFAOYSA-N Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(N)nn2 Chemical compound Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(N)nn2 JFPQJONXEVRXFI-UHFFFAOYSA-N 0.000 description 1
- ODPQIVUHVCGRLP-UHFFFAOYSA-N Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1ccc(C(NCCN3CCCC3)=O)nc1)nn2 Chemical compound Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1ccc(C(NCCN3CCCC3)=O)nc1)nn2 ODPQIVUHVCGRLP-UHFFFAOYSA-N 0.000 description 1
- YEGWRBLGTMVLMJ-UHFFFAOYSA-N Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1cccc(OCCN3CCCC3)c1)nn2 Chemical compound Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1cccc(OCCN3CCCC3)c1)nn2 YEGWRBLGTMVLMJ-UHFFFAOYSA-N 0.000 description 1
- GPAGRRIIGMGNMD-UHFFFAOYSA-N Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 Chemical compound Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 GPAGRRIIGMGNMD-UHFFFAOYSA-N 0.000 description 1
- RTXLIJJDHXCIIF-UHFFFAOYSA-N Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1nc(C)nc(OCCN3CCCC3)c1)nn2 Chemical compound Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1nc(C)nc(OCCN3CCCC3)c1)nn2 RTXLIJJDHXCIIF-UHFFFAOYSA-N 0.000 description 1
- PFHBGGIVIPCMIS-UHFFFAOYSA-N Cc1cc(-c2cccc(O)c2F)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c2cccc(O)c2F)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 PFHBGGIVIPCMIS-UHFFFAOYSA-N 0.000 description 1
- RGCPQJWQLGCWGM-UHFFFAOYSA-N Cc1cc(Br)cc2c1nc(N)nn2 Chemical compound Cc1cc(Br)cc2c1nc(N)nn2 RGCPQJWQLGCWGM-UHFFFAOYSA-N 0.000 description 1
- BCJNHDIVYXFDMA-UHFFFAOYSA-N Cc1cc2nc(Nc(cc3)ccc3S(N(C)CCN3CCCC3)(=O)=O)nnc2cc1-c1cc(OC)ccc1Cl Chemical compound Cc1cc2nc(Nc(cc3)ccc3S(N(C)CCN3CCCC3)(=O)=O)nnc2cc1-c1cc(OC)ccc1Cl BCJNHDIVYXFDMA-UHFFFAOYSA-N 0.000 description 1
- HVKLKXJHEXZHRA-UHFFFAOYSA-N Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OCCCN1CCCC1)nn2 Chemical compound Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OCCCN1CCCC1)nn2 HVKLKXJHEXZHRA-UHFFFAOYSA-N 0.000 description 1
- PKACVUDGDZAACR-UHFFFAOYSA-N Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc(cc1Cl)ccc1Cl)nn2 Chemical compound Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc(cc1Cl)ccc1Cl)nn2 PKACVUDGDZAACR-UHFFFAOYSA-N 0.000 description 1
- KZCMQDWEVKEHLN-UHFFFAOYSA-N Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1cccc(S(NCCN(C)C)(=O)=O)c1)nn2 Chemical compound Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1cccc(S(NCCN(C)C)(=O)=O)c1)nn2 KZCMQDWEVKEHLN-UHFFFAOYSA-N 0.000 description 1
- ZJQVYURHZFRKLA-UHFFFAOYSA-N Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1ccncc1)nn2 Chemical compound Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1ccncc1)nn2 ZJQVYURHZFRKLA-UHFFFAOYSA-N 0.000 description 1
- DMDJUVDEWDKOOC-UHFFFAOYSA-N Cc1cccc(Cl)c1-c(cc1C)cc2c1nc(Nc1ccncc1)nn2 Chemical compound Cc1cccc(Cl)c1-c(cc1C)cc2c1nc(Nc1ccncc1)nn2 DMDJUVDEWDKOOC-UHFFFAOYSA-N 0.000 description 1
- MISJXJNFFYOIPX-UHFFFAOYSA-N Cc1ccccc1-c(c(OC)c1)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1ccccc1-c(c(OC)c1)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 MISJXJNFFYOIPX-UHFFFAOYSA-N 0.000 description 1
- RHGHRAGIGDLNSO-UHFFFAOYSA-N Cc1ccncc1-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)nn2 Chemical compound Cc1ccncc1-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)nn2 RHGHRAGIGDLNSO-UHFFFAOYSA-N 0.000 description 1
- BGVRDWFMIZTBBG-UHFFFAOYSA-N Cc1n[o]c(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OC)nn2 Chemical compound Cc1n[o]c(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OC)nn2 BGVRDWFMIZTBBG-UHFFFAOYSA-N 0.000 description 1
- RXBTXEBGONSTPB-UHFFFAOYSA-N Cc1n[o]c(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OCCN1CCN(C)CC1)nn2 Chemical compound Cc1n[o]c(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OCCN1CCN(C)CC1)nn2 RXBTXEBGONSTPB-UHFFFAOYSA-N 0.000 description 1
- CDCZPFYGOFSGLY-UHFFFAOYSA-N NC(C=C1)=CN(CCCN2CCCC2)C1=O Chemical compound NC(C=C1)=CN(CCCN2CCCC2)C1=O CDCZPFYGOFSGLY-UHFFFAOYSA-N 0.000 description 1
- WRXNJTBODVGDRY-UHFFFAOYSA-N NCCN1CCCC1 Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 1
- ROCVGJLXIARCAC-UHFFFAOYSA-N Nc(c(O)c1)ccc1O Chemical compound Nc(c(O)c1)ccc1O ROCVGJLXIARCAC-UHFFFAOYSA-N 0.000 description 1
- ZKLDPEWNXLYZLU-UHFFFAOYSA-N O=C(c1c[s]c(Br)n1)NCCN1CCCC1 Chemical compound O=C(c1c[s]c(Br)n1)NCCN1CCCC1 ZKLDPEWNXLYZLU-UHFFFAOYSA-N 0.000 description 1
- DIYRIYJMMLUTQP-UHFFFAOYSA-N O=S(c(cc1)ccc1Br)(NCCN1CCCC1)=O Chemical compound O=S(c(cc1)ccc1Br)(NCCN1CCCC1)=O DIYRIYJMMLUTQP-UHFFFAOYSA-N 0.000 description 1
- PJGOLCXVWIYXRQ-UHFFFAOYSA-N O=S(c1cc(Br)ccc1)(Cl)=O Chemical compound O=S(c1cc(Br)ccc1)(Cl)=O PJGOLCXVWIYXRQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of benzotriazine compounds to treat disorders.
- c-Src plays a major role in the growth, progression and metastasis of a large number of cancers.
- c-Src can be the transforming element of the oncogenic Rous sarcoma retrovirus. Subsequently, it has been demonstrated that c-Src kinase can have the oncogenic potential. Gene knockout experiments suggest that inhibition of some members of the Src family might have potential therapeutic benefit.
- Tyrosine kinases phosphorylate tyrosine residues in peptides and proteins. These enzymes are key elements in the regulation of cell signaling including cell proliferation and cell differentiation.
- Protein TKs comprise the receptor TKs, including the epidermal growth family members (HERl and HER2 for example), platelet derived growth factor (PDGF) and kinases that play a role in angiogenesis (Tie-2 and KDR for example), and the cellular or non-receptor kinases, which include members of the Src family.
- c-Src TK is one of three members of the Src family expressed ubiquitously.
- c-Src is expressed at low levels in most cell types and, in the absence of the appropriate extracellular stimuli, maintained in an inactive conformation through phosphorylation of a regulatory tyrosine domain at Tyr530.
- Activation of c-Src occurs through dephosphorylation of the Tyr530 site and phosphorylation of a second tyrosine, Tyr419, present in the kinase domain of the enzyme.
- Src kinase modulates signal transduction through multiple oncogenic pathways, including EGFR, HER2, PDGFR, FGFR and NEGFR.
- blocking signaling through the inhibition of the kinase activity of Src can be an effective means of modulating aberrant pathways that drive the oncogenic transformation of cells.
- c-Src TK activity has been associated with adhesion and cytoskeletal changes both in tumor cells and otherwise, ultimately resulting in an invasive phenotype that may be motile.
- c-Src TK activity has been shown to be an important component in the epithelial to mesenchymal transition that occurs in the early stages of invasion of carcinoma cells.
- c-Src activity is also known to be essential in the turnover of local adhesions, a critical cell-motility component.
- c-Src inhibition markedly reduces the rate of lymph and liver metastases.
- Clinical data supports the link between misregulated Src activity and the increased invasive potential of tumor cells, hi colon tumors, increased c-Src TK activity has been shown to correlate to tumor progression, with the highest activity found in metastatie tissue. Increased Src activity in colon tumors might be an indicator of poor prognosis.
- enhancement of Src kinase activity has been reported, and in transitional cell carcinoma of the bladder, c-Src activity peaked as superficial tumors became muscle invasive.
- Increased c-Src TK activity results in breakdown of the E-cadherin-mediated epithelial cell-cell adhesion, which can be restored by Src inhibition.
- Intimate connections between increased NEGF activity, Src activity, and cellular barrier function related to vascular leak have been also demonstrated.
- Inhibition of Src results in decrease in vascular leak when exogenous NEGF is administered in in vivo studies. Examples where excessive vascular permeability leads to particularly deleterious effects include pulmonary edema, cerebral edema, and cardiac edema.
- NEGF-mediated edema has been shown to involve intracellular signaling by Src family kinases, protein kinase C, and Akt kinase.
- Rho-associated kinases have been linked to thrombin-mediated vascular leakage, and protein kinase C to T ⁇ F-induced leakage.
- MLCK myosin light chain kinase
- MLC myosin light chain
- a general approach to the inhibition of vascular leakage can be to interfere with any of the underlying mechanistic pathways, whether by inhibition of kinase signaling or the intercellular contractile apparatus or other cellular processes. This can then lead to potential treatments for edema and its associated pathologies. For example, inhibiting edema formation should be beneficial to overall patient outcome in situations such as inflammation, allergic diseases, cancer, cerebral stroke, myocardial infarction, pulmonary and cardiac insufficiency, renal failure, and retinopathies, to name a few. Furthermore, as edema is a general consequence of tissue hypoxia, it can also be concluded that inhibition of vascular leakage represents a potential approach to the treatment of tissue hypoxia.
- interruption of blood flow by pathologic conditions such as thrombus formation
- medical intervention such as cardioplegia, organ transplantation, and angioplasty
- inhibitors of vascular leakage especially as in the case of Src inhibitors.
- a small molecule inhibitor of c-Src can be beneficial for the treatment of several disease states.
- the present invention provides methods of use for certain chemical compounds such as kinase inhibitors for treatment of various diseases, disorders, and pathologies, for example, cancer, and vascular disorders, such as myocardial infarction (MI), stroke, or ischemia.
- chemical compounds such as kinase inhibitors for treatment of various diseases, disorders, and pathologies, for example, cancer, and vascular disorders, such as myocardial infarction (MI), stroke, or ischemia.
- the benzotriazine compounds described in this invention may block the enzymatic activity of some or many of the members of the Src family, in addition to blocking the activity of other receptor and non-receptor kinases.
- Such compounds may be beneficial for treatment of the diseases where disorders affect cell motility, adhesion, and cell cycle progression, and in addition, diseases with related hypoxic conditions, osteoporosis and conditions, which result from or are related to increases in vascular permeability, inflammation or respiratory distress, tumor growth, invasion, angiogenesis, metastases and apoptosis.
- kinase inhibitors that can be used to bring about beneficial therapeutic results include inhibitors of Src kinase.
- each of A can be (CH)o- ⁇ . N, N ⁇ , O, S, or a part of a ring fusion to form a second ring, where the second ring can be an aromatic, a heteroaromatic, a bicyclic aromatic, a bicyclic aromatic heterocyclic ring, or a bicyclic with only the first ring being aromatic or heteroaromatic;
- each of B can be (CH)o- ⁇ , N, NH, O, S, ora part of a ring fusion to form a second ring, where the second ring can be an aromatic, a heteroaromatic, a bicyclic aromatic, a bicyclic aromatic heterocyclic ring, or a bicyclic with only the first ring being aromatic or heteroaromatic, with the further proviso that if each B is (CH)o, R 3 can be any substitutent described below other than hydrogen bonded directly to the position 7 of the adjacent ring;
- R 0 can be H or lower alkyl
- L can be a bond, or a substituted or unsubstituted alkyl, alkenyl, or alkynyl linking moiety
- Ri can be C(R*) 3 , OR, N(R') 2 . NR'C(O)R, NR'C(O)O(R), NR'C(O)N(R') 2 , SR', C(O)(O)R, C(O), C(O)N(R') 2 , SO 3 R, OSO 2 R', SO 2 R, SOR, S(O)N(R) 2 , OS(O)(O)N(R') 2 , S(O)(O)N(R * ) 2 , S(O)N(R) 2 , PO 4 R', OPO 2 R, PO 3 R', PO 2 R', or a 3-6 membered heterocycle with one or more heterocyclic atoms, with each heteroatom being capable of carrying any R' group on it, wherein R' can be hydrogen, lower alkyl, alkyl- hydroxyl, thiol-alkyl, alkyl-thiol, aminoal
- R 2 is a substitutent situated at position 5,6 or 8 of the ring, wherein R 2 can be methyl, ethyl, n-propyl, wopropyl, n-butyl, z ' so-butyl, tert-butyl, tso-pentyl, phenyl, substituted phenyl, halogen, branched or unbranched alkylamino, branched or unbranched aminoalkyl, branched or unbranched alkyloxo, branched or unbranched oxyalkyl, branched or unbranched thioalkyl, branched or unbranched alkylthiol, CF 3 , sulfonamido, substituted sulfonamido, sulfonate, sulfonate ester, phosphate, phosphate ester, phosphonate, phosphonate ester, carboxo, amido, ureido
- R 3 can be hydrogen, alkyl, alkoxy, halogen, CF 3 , cyano, substituted alkyl, or hydroxyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, C(R") 3 , OR", N(R") 2 , NR"C(O)R", NR"C(O)NR", R", C(O)(O)R", OC(O)R", C(O)N(R") 2 , C(O), OC(O)N(R") 2 , SO 3 R", OSO 2 R", SO 2 R", SOR", PO 4 R", OPO 2 R", PO 3 R", PO 2 R", wherein R" can be hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, lower alkyl, branched lower alkyl, alkyl-hydroxyl, branched alkyl-hydroxyl, amino-alkyl, branched amino-alkyl, alkyl-a
- articles of manufacture including packaging material and a pharmaceutical composition contained within the packaging material, wherein the packaging material includes a label which indicates that the pharmaceutical composition can be used for treatment of disorders associated with compromised vasculostasis, and wherein the pharmaceutical composition includes at least one compound of structure (I).
- articles of manufacture including packaging material and a pharmaceutical composition contained within the packaging material, wherein the packaging material includes a label which indicates that the pharmaceutical composition can be used for treatment of disorders associated with vascular permeability leakage or compromised vasculostasis, such as myocardial infarction, stroke, congestive heart failure, an ischemia or reperfusion injury, cancer, arthritis or other arthropathy, retinopathy or vitreoretinal disease, macular degeneration, autoimmune disease, vascular leakage syndrome, inflammatory disease, edema, transplant rejection, burn, or acute or adult respiratory distress syndrome (ARDS) and wherein the pharmaceutical composition includes at least one compound of structure (I).
- disorders associated with vascular permeability leakage or compromised vasculostasis such as myocardial infarction, stroke, congestive heart failure, an ischemia or reperfusion injury, cancer, arthritis or other arthropathy, retinopathy or vitreoretinal disease, macular degeneration, autoimmune disease, vascular leakage syndrome, inflammatory
- a disorder associated with compromised vasculostasis including the administration of a therapeutically effective amount of at least one compound of structure (I) or pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers thereof, to a subject in need of such treatment.
- methods of treating a disorder associated with compromised vasculostasis including the administration of a therapeutically effective amount of at least one compound of structure (I), or pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers thereof, in combination with an anti-inflammatory, chemotherapeutic agent, immunomodulatory agent, therapeutic antibody or a protein kinase inhibitor, to a subject in need of such treatment.
- methods of treating a subject having or at risk of having a disorder selected from myocardial infarction, vascular leakage syndrome (NLS), cancer, stroke, ARDS, burns, arthritis, edema, retinopathy or vitreoretinal disease, ischemic or reperfusion related tissue injury or damage, autoimmune disease, transplant rejection, inflammatory disease including administering to the subject a therapeutically effective amount of at least one compound of structure (I), thereby treating the subject.
- a disorder selected from myocardial infarction, vascular leakage syndrome (NLS), cancer, stroke, ARDS, burns, arthritis, edema, retinopathy or vitreoretinal disease, ischemic or reperfusion related tissue injury or damage, autoimmune disease, transplant rejection, inflammatory disease
- processes for making a pharmaceutical composition including combining a combination of at least one compound of structure (I) or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms salts and individual diastereomers thereof and a pharmaceutically acceptable carrier.
- heterocyclic when used to describe an aromatic ring, refer to the aromatic ring containing at least one heteroatom.
- heteroatom refers to any atom other than carbon, for example, N, O, or S.
- aromatic refers to a cyclically conjugated molecular entity with a stability, due to delocalization, significantly greater than that of a hypothetical localized structure, such as the Kekule structure.
- heterocyclic when not used to describe an aromatic ring, refers to cyclic (i.e., ring-containing) groups other than aromatic groups, the cyclic group being formed by between 3 and about 14 carbon atoms and at least one heteroatom described above.
- substituted heterocyclic refers, for both aromatic and non-aromatic structures, to heterocyclic groups further bearing one or more substituents described above.
- alkyl refers to a monovalent straight or branched chain hydrocarbon group having from one to about 12 carbon atoms, for example, methyl, ethyl, n-propyl, wopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl (also known as n- amyl), n-hexyl, and the like.
- substituted alkyl refers to alkyl groups further bearing one or more substituents such as hydroxy, alkoxy, mercapto, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy, halogen, cyano, nitro, amino, amido, aldehyde, acyl, oxyacyl, carboxyl, sulfonyl, sulfonamide, sulfuryl, and the like.
- substituents such as hydroxy, alkoxy, mercapto, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy, halogen, cyano, nitro, amino, amido, aldehyde, acyl,
- lower alkyl refers to alkyl groups having from 1 to about 6 carbon atoms.
- alkenyl refers to straight-chained or branched hydrocarbyl groups having at least one carbon-carbon double bond, and having between about 2 and about 12 carbon atoms
- substituted alkenyl refers to alkenyl groups further bearing one or more substituents described above.
- alkynyl refers to straight-chained or branched hydrocarbyl groups having at least one carbon-carbon triple bond, and having between about 2 and about 12 carbon atoms
- substituted alkynyl refers to alkynyl groups further bearing one or more substituents described above.
- aryl refers to aromatic groups having between about 5 and about 14 carbon atoms and the term “substituted aryl” refers to aryl groups further bearing one or more substituents described above.
- heteroaryl refers to aromatic rings, where the ring structure is formed by between 3 and about 14 carbon atoms and by at least one heteroatom described above, and the term “substituted heteroaryl” refers to heteroaryl groups further bearing one or more substituents described above.
- alkoxy refers to the moiety — O— alkyl, wherein alkyl is as defined above, and the term “substituted alkoxy” refers to alkoxy groups further bearing one or more substituents described above.
- cycloalkyl refers to alkyl groups having between 3 and about 8 carbon atoms arranged as a ring, and the term “substituted cycloalkyl” refers to cycloalkyl groups further bearing one or more substituents described above.
- alkylaryl refers to alkyl-substituted aryl groups and the term “substituted alkylaryl” refers to alkylaryl groups further bearing one or more substituents described above.
- arylalkyl refers to aryl-substituted alkyl groups and the term “substituted arylalkyl” refers to arylalkyl groups further bearing one or more substituents described above.
- arylalkenyl refers to aryl-substituted alkenyl groups and the term “substituted arylalkenyl” refers to arylalkenyl groups further bearing one or more substituents described above.
- arylalkynyl refers to aryl-substituted alkynyl groups and the term “substituted arylalkynyl” refers to arylalkynyl groups further bearing one or more substituents described above.
- arylene refers to divalent aromatic groups having between 5 and about 14 carbon atoms and the term “substituted arylene” refers to arylene groups further bearing one or more substituents described above.
- kinase refers to any enzyme that catalyzes the addition of phosphate groups to a protein residue; for example, serine and threonine kinases catalyze the addition of phosphate groups to serine and threonine residues.
- Src kinase refers to the related homologs or analogs belonging to the mammalian family of Src kinases, including, for example, c-Src, Fyn, Yes and Lyn kinases and the hematopoietic-restricted kinases Hck, Fgr, Lck and Blk.
- Src kinase signaling pathway and “Src cascade” refer to both the upstream and downstream components of the Src signaling cascade.
- terapéuticaally effective amount refers to the amount of the compound or pharmaceutical composition that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician, e.g., restoration or maintenance of vasculostasis or prevention of the compromise or loss or vasculostasis; reduction of tumor burden; reduction of morbidity and/or mortality.
- composition refers to the fact that the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- administration of a compound or “administering a compound” refer to the act of providing a compound of the invention or pharmaceutical composition to the subject in need of treatment.
- antibody refers to intact molecules of polyclonal or monoclonal antibodies, as well as fragments thereof, such as Fab and F(ab') 2 , Fv and SCA fragments which are capable of binding an epitopic determinant.
- vasculostasis refers to the maintenance of the homeostatic vascular functioning leading to the normal physiologic functioning.
- vasculostatic agents refers to agents that seek to address conditions in which vasculostasis is compromised by preventing the loss of or restoring or maintaining vasculostasis.
- compounds having the structure (I) are provided for treatment of various diseases, disorders, and pathologies, as well as pharmaceutically acceptable salts, hydrates, solvates, crystal forms, N-oxides, and individuals diastereoners of compounds having the structure (I):
- each of A can be (CH) 0 _ ⁇ , N, NH, O, S, or a part of a ring fusion to form a second ring, where the second ring can be an aromatic, a heteroaromatic, a bicyclic aromatic, a bicyclic aromatic heterocyclic ring, or a bicyclic with only the first ring being aromatic or heteroaromatic;
- each of B can be (CH) 0 - ⁇ , N, MI, O, S, ora part of a ring fusion to form a second ring, where the second ring can be an aromatic, a heteroaromatic, a bicyclic aromatic, a bicyclic aromatic heterocyclic ring, or a bicyclic with only the first ring being aromatic or heteroaromatic, with the further proviso that if each B is (CH) 0 , R 3 can be any substitutent described below, other than hydrogen, bonded directly to the position 7 of the adjacent ring;
- R 0 can be H or lower alkyl
- L can be a bond, or a substituted or unsubstituted alkyl, alkenyl, or alkynyl linking moiety
- Ri can be C(R') 3 , OR', N(R) 2 , NR'C(O)R, NR'C(O)O(R')- NR'C(O)N(R')2, SR, C(O)(O)R', C(O), C(O)N(R) 2 , SO 3 R, OSO 2 R, SO 2 R', SOR, S(O)N(R') 2 , OS(O)(O)N(R') 2 , S(O)(O)N(R') 2 .
- R can be hydrogen, lower alkyl, alkyl- hydroxyl, thiol-alkyl, alkyl-thiol, aminoalkyl, alkylamino, branched alkyl, branched alkyl hydroxyl, branched thio-alkyl, branched alkyl-thiol, branched aminoalkyl, branched alkylamino, or a closed 3-6 membered carbocycle or heterocycle, with each heteroatom in the 3-6 membered heterocycle being capable of carrying any R' group on it, and wherein each R can be independent in case there is more than one R';
- R 2 is a substitutent situated at position 5,6 or 8 of the ring, wherein R 2 can be methyl, ethyl, n-propyl, z ' sopropyl, n-butyl, iso-butyl, tert-butyl, tsopentyl, phenyl, substituted phenyl, halogen, branched or unbranched alkylamino, branched or unbranched aminoalkyl, branched or unbranched alkyloxo, branched or unbranched oxyalkyl, branched or unbranched thioalkyl, branched or unbranched alkylthiol, CF 3 , sulfonamido, substituted sulfonamido, sulfonate, sulfonate ester, phosphate, phosphate ester, phosphonate, phosphonate ester, carboxo, amido, ureido,
- R 3 can be hydrogen, alkyl, alkoxy, halogen, CF 3 , cyano, substituted alkyl, or hydroxyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, C(R") , OR", N(R") 2 , NR"C(O)R", NR"C(O)NR", R", C(O)(O)R", OC(O)R", C(O)N(R") 2 , C(O), OC(O)N(R") 2 , SO 3 R", OSO 2 R", SO 2 R", SOR", PO 4 R", OPO 2 R", PO 3 R", PO 2 R", wherein R" can be hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, lower alkyl, branched lower alkyl, alkyl-hydroxyl, branched alkyl-hydroxyl, amino-alkyl, branched amino-alkyl, alkyl-amin
- n is an integer that can have value between 1 and 5, with the further proviso that if n > 2, then each group R is independent of the other groups R 3 ,
- the compounds and methods of the present invention are useful in treating a variety of disorders associated with compromised vasculostasis and other disorders, including but not limited to, for example: stroke, cardiovascular disease, myocardial infarction, congestive heart failure, cardiomyopathy, myocarditis, ischemic heart disease, coronary artery disease, cardiogenic shock, vascular shock, pulmonary hypertension, pulmonary edema (including cardiogenic pulmonary edema), cancer, pleural effusions, rheumatoid arthritis, diabetic retinopathy, retinitis pigmentosa, and retinopathies, including diabetic retinopathy and retinopathy of prematurity, inflammatory diseases, restenosis, edema (including edema associated with pathologic situations such as cancers and edema induced by medical interventions such as chemotherapy), asthma, acute or adult respiratory distress syndrome
- agents e.g., chemotherapeutic agents or protein therapeutic agents described below
- T-cell mediated hypersensitivity diseases including contact hypersensitivity, delayed- type hypersensitivity, and gluten-sensitive enteropathy (Celiac disease); Type 1 diabetes; psoriasis; contact dermatitis (including that due to poison ivy); Hashimoto's thyroiditis; Sjogren's syndrome; Autoimmune Hyperthyroidism, such as Graves' disease; Addison's disease (autoimmune disease of the adrenal glands); autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome); autoimmune alopecia; pernicious anemia; vitiligo; autoimmune hypopituatarism; Guillain-Barre syndrome; other autoimmune diseases; cancers, including those where kinases such as Src-family kinases are activated or overexpressed, such as colon carcinoma and thymoma, or cancers where kinase activity facilitates tumor growth or survival; glomerulonephritis, serum sickness; uticaria; allergic diseases such as respiratory allergies
- Src-family tyrosine kinases other than Lck are important in the Fc gamma receptor induced respiratory burst of neutrophils as well as the Fc gamma receptor responses of monocytes and macrophages.
- the compositions and methods of the present invention may be useful in inhibiting the Fc gamma induced respiratory burst response in neutrophils, and may also be useful in inhibiting the Fc gamma dependent production of TNF alpha.
- the ability to inhibit Fc gamma receptor dependent neutrophil, monocyte and macrophage responses would result in additional anti-inflammatory activity for the compounds employed in invention methods.
- compositions and methods of the present invention may also be useful in the treatment of autoimmune glomerulonephritis and other instances of glomerulonephritis induced by deposition of immune complexes in the kidney that trigger Fc gamma receptor responses and which can lead to kidney damage.
- Fc epsilon receptor induced degranulation of mast cells and basophils that plays an important role in asthma, allergic rhinitis, and other allergic disease.
- Fc epsilon receptors are stimulated by IgE-antigen complexes.
- Compounds employed in the methods of the present invention may inhibit the Fc epsilon induced degranulation responses.
- the ability to inhibit Fc epsilon receptor dependent mast cell and basopbil responses may result in additional anti-inflammatory activity for the present compounds beyond their effect on T cells.
- the present invention also provides articles of manufacture comprising packaging material and a pharmaceutical composition contained within the packaging material, wherein the packaging material comprises a label which indicates that the pharmaceutical composition can be used for treatment of disorders and wherein the pharmaceutical composition comprises a compound according to the present invention.
- the invention provides a pharmaceutical composition including a therapeutic agent and a compound of the invention, wherein the compound is present in a concentration effective to reduce vascular leakage associated with indications or therapeutic agents which have vascular leak as a side effect.
- administration of a compound of the invention can be in conjunction with E -2, immunotoxins, antibodies or chemotherapeutics.
- IL-2, immunotoxin, antibody or chemotherapeutic concentration can be determined by one having ordinary skill in the art according to standard treatment regimen or, for example, as determined by an in vivo animal assay.
- the present invention also provides pharmaceutical compositions comprising IL-2, immunotoxin, antibody or chemotherapeutic and at least one invention compound in an amount effective for inhibiting vascular permeability, and a pharmaceutically acceptable vehicle or diluent.
- the compositions of the present invention may contain other therapeutic agents, and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques known in the art of pharmaceutical formulation.
- the compounds of the invention may be formulated into therapeutic compositions as natural or salt forms.
- Pharmaceutically acceptable non-toxic salts include the base addition salts (formed with free carboxyl or other anionic groups) which may be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino-ethanol, histidine, procaine, and the like.
- Such salts may also be formed as acid addition salts with any free cationic groups and will generally be formed with inorganic acids such as, for example, hydrochloric, sulfuric, or phosphoric acids, or organic acids such as acetic, citric, p-toluenesulfonic, methanesulfonic acid, oxalic, tartaric, mandelic, and the like.
- Salts of the invention include amine salts formed by the protonation of an amino group with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like.
- Salts of the invention also include amine salts formed by the protonation of an amino group with suitable organic acids, such as p-toluenesulfonic acid, acetic acid, and the like.
- suitable organic acids such as p-toluenesulfonic acid, acetic acid, and the like.
- Additional excipients which are contemplated for use in the practice of the present invention are those available to those of ordinary skill in the art, for example, those found in the United States Pharmacopeia Vol. XXII and National Formulary Vol. XVII, U.S. Pharmacopeia Convention, Inc., Rockville, MD (1989), the relevant contents of which is incorporated herein by reference, i addition, polymorphs of the invention compounds are included in the present invention.
- compositions of the invention may be administered by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, intrathecal, or intracisternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents.
- suitable means for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, intrathecal, or intracisternal injection or infusion techniques (e.g., as
- the present compounds may, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps.
- the present compounds may also be administered liposomally.
- mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated.
- the method can also be practiced in other species, such as avian species (e.g., chickens).
- compositions for the administration of the compounds of this embodiment either alone or in combination with IL-2, immunotoxin, antibody or chemotherapeutic may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients.
- the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
- the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.
- compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated to form osmotic therapeutic tablets for control release.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy- propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidorie, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbit
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n- propyl, ?-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., sodium EDTA
- suspending agent e.g., sodium EDTA
- preservatives e.g., sodium EDTA, sodium bicarbonate, sodium bicarbonate
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a parenterally-acceptable diluent or solvent or cosolvent or complexing agent or dispersing agent or excipient or combination thereof, for example 1,3-butanediol, polyethylene glycols, polypropylene glycols, ethanol or other alcohols, povidones, various brands of TWEEN surfactant, sodium dodecyl sulfate, sodium deoxycholate, dimethylacetamide, polysorbates, poloxamers, cyclodextrins, lipids, and excipients such as inorganic salts (e.g., sodium chloride), buffering agents (e.g., sodium citrate, sodium phosphate), and sugars (e.g., saccharose and dextrose).
- a parenterally-acceptable diluent or solvent or cosolvent or complexing agent or dispersing agent or excipient or combination thereof for example 1,3-butan
- Suitable vehicles and solvents that may be employed are water, dextrose solutions, Ringer's solutions and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- these pharmaceutical compositions may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in the latest edition of "Remington's Pharmaceutical Sciences” (Mack Publishing Co, Easton Pa.). Suitable routes may, for example, include oral or transmucosal administration; as well as parenteral delivery, including intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration.
- the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline.
- penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds maybe prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow, for the preparation of highly concentrated solutions.
- the compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- Such materials are cocoa butter and polyethylene glycols.
- creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed.
- topical application shall include mouthwashes and gargles).
- the invention compounds are administered in combination with an anti-inflammatory agent, antihistamines, chemotherapeutic agent, immunomodulator , therapeutic antibody or a protein kinase inhibitor, e.g., a tyrosine kinase inhibitor, to a subject in need of such treatment.
- chemotherapeutic agents include antimetabolites, such as methotrexate, DNA cross-linking agents, such as cisplatin/carboplatin; alkylating agents, such as canbusil; topoisomerase I inhibitors such as dactinomicin; microtubule inhibitors such as taxol (paclitaxol), and the like.
- chemotherapeutic agents include, for example, a vinca alkaloid, mitomycin-type antibiotic, bleomycin-type antibiotic, antifolate, colchicine, demecoline, etoposide, taxane, anthracycline antibiotic, doxorubicin, daunorubicin, carminomycin, epirubicin, idarubicin, mithoxanthrone, 4-dimethoxy-daunomycin, 11-deoxydaunorabicin, 13- deoxydaunorubicin, adriamycin-14-benzoate, adriamycin-14-octanoate, adriamycin-14- naphthaleneacetate, amsacrine, carmustine, cyclophosphamide, cytarabine, etoposide, lovastatin, melphalan, topetecan, oxalaplatin, chlorambucil, methtrex
- therapeutic antibodies include antibodies directed against the HER2 protein, such as trastuzumab; antibodies directed against growth factors or growth factor receptors, such as bevacizumab, which targets vascular endothelial growth factor, and OSI-774, which targets epidermal growth factor; antibodies targeting integrin receptors, such as Nitaxin (also known as MEDI-522), and the like.
- Classes of anticancer agents suitable for use in compositions and methods of the present invention include, but are not limited to: 1) alkaloids, including, microtubule inhibitors (e.g., Nincristine, Vinblastine, and Vindesine, etc.), microtubule stabilizers (e.g., Paclitaxel [Taxol], and Docetaxel, Taxotere, etc.), and chromatin function inhibitors, including, topoisomerase inhibitors, such as, epipodophyllotoxins (e.g., Etoposide [VP-16], and Teniposide [VM- 26], etc.), and agents that target topoisomerase I (e.g., Camptothecin and Isirinotecan [CPT-11], etc.); 2) covalent D ⁇ A-binding agents [alkylating agents], including, nitrogen mustards (e.g., Mechlorethamine, Chlorambucil, Cyclophosphamide, Ifosphamide, and Busulfan [
- the pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions.
- other therapeutic agents include the following: cyclosporins (e.g., cyclosporin A), CTLA4-Ig, antibodies such as ICAM-3, anti-IL-2 receptor (Anti-Tac), anti-CD45RB, anti-CD2, anti-CD3 (OKT-3), anti-CD4, anti-CD80, anti-CD86, agents blocking the interaction between CD40 and gp39, such as antibodies specific for CD40 and/or gp39 (i.e., CD154), fusion proteins constructed from CD40 and gp39 (CD40Ig and CD8gp39), inhibitors, such as nuclear translocation inhibitors, of NF-kappa B function, such as deoxyspergualin (DSG), cholesterol biosynthesis inhibitors such as HMG CoA reductase inhibitors (lovastatin and simvastatin), non-steroidal anti
- cytokine encompasses chemokines, interleukins, lymphokines, monokines, colony stimulating factors, and receptor associated prqteins, and functional fragments thereof.
- functional fragment refers to a polypeptide or peptide which possesses biological function or activity that is identified through a defined functional assay.
- the cytokines include endothelial monocyte activating polypeptide II (EMAP- II), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (G-CSF), macrophage- CSF (M-CSF), IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-12, and IL-13, interferons, and the like and which is associated with a particular biologic, morphologic, or phenotypic alteration in a cell or cell mechanism.
- EMP- II endothelial monocyte activating polypeptide II
- GM-CSF granulocyte-macrophage-CSF
- G-CSF granulocyte-CSF
- M-CSF macrophage- CSF
- IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-12, and IL-13 interferons
- an appropriate dosage level can generally be between about 0.01 and about 500 mg per 1 kg of patient body weight per day which can be administered in single or multiple doses.
- the dosage level can be between about 0.01 and about 250 mg/kg per day; more narrowly, between about 0.5 and about 100 mg/kg per day.
- a suitable dosage level can be between about 0.01 and about 250 mg/kg per day, between about 0.05 and about 100 mg/kg per day, or between about 0.1 and about 50 mg/kg per day, or about 1.0 mg/kg per day.
- the dosage can be between about 0.05 and about 0.5 mg/kg per day, or between about 0.5 and about 5 mg/kg per day, or between about 5 and about 50 mg/kg per day.
- the compositions can be provided in the form of tablets containing between about 1.0 and about 1,000 mg of the active ingredient, for example, about 1.0, about 5.0, about 10.0, about 15.0, about'20.0, about 25.0, about 50.0, about 75.0, about lOO.O, about 150.0, about 200.0, about 250.0, about 300.0, about 400.0, about 500.0, about 600.0, about 750.0, about 800.0, about 900.0, and about 1,000.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
- the compounds can be administered on a regimen of 1 to 4 times per day, such as once or twice per day. There may be a period of no administration followed by another regimen of administration.
- administration of the compound is closely associated with the schedule of IL- 2 administration.
- administration can be prior to, simultaneously with or immediately following IL-2 administration.
- Compounds of the present invention can be used, alone or in combination with an effective amount of a therapeutic antibody (or therapeutic fragment thereof), a chemotherapeutic or an immunotoxic agent, for treatment of tumors. While doxorubicin, docetaxel, or taxol are described in the present application as illustrative examples of chemotherapeutic agents, it should be understood that the invention includes combination therapy including a compound of the invention, including but not limited to vasculostatic agents, such as tyrosine, serine or threonine kinase inhibitors, for example, Src-family inhibitors, and any chemotherapeutic agent or therapeutic antibody.
- vasculostatic agents such as tyrosine, serine or threonine kinase inhibitors, for example, Src-family inhibitors, and any chemotherapeutic agent or therapeutic antibody.
- Reverse-phase HPLC chromatography was carried out on Gilson 215 liquid handler equipped with Waters SymmetryShieldTM RP18 7 ⁇ m (40 x 100mm) Prep-Pak cartridge.
- Mobile phase consisted of standard acetonitrile (ACN) and DI Water, each with 0.1% TFA added. Purification was carried out at a flow rate of 40mL/ min, and a gradient such that the peak of interest was eluted between 12-15 min in a 30 min run.
- one of three methods A, B, or C can be used for synthesizing some of the compounds of the present invention.
- Those having ordinary skill in the art can determine, depending on variety of factors, including the particular compound that is sought to be made, whether to selected the method A, B or C.
- the synthetic method A is shown by the reaction scheme (II). About 1 equivalent of compound 1 was mixed with 2 equivalent of cynamide in a vial. The mixture was heated to about 100°C until the mixture was completely melted. The mixture was cooled down to room temperature and concentrated HCI was added. The mixture was then again heated at about 100°C for about 40 minutes and cooled down in ice water. About 14 moles of NaOH were carefully added to the above reaction mixture followed by heating the mixture at about 100°C for about 2 hours, and by cooling down to room temperature.
- Compound 3 was dissolved in N, N-dimethylacetamide in a vial with a septum. Catalytic amount of 10% palladium on carbon was added to the mixture. A balloon filled with hydrogen was placed on the top of the vial. The mixture was stirred at room temperature for about 2 hours. Celite was used to remove the palladium and carbon. Solvent was removed under vacuum and compound 4, shown by the reaction scheme (II), was isolated.
- the synthetic method B is shown by the reaction scheme (III).
- Compounds 1, 2, 3, and 4 were consecutively prepared and isolated as described in Method A. About 1 equivalent of compound 4 was dissolved in an aniline followed by adding about 2 equivalents of sulfamic acid. The mixture was heated at about 200°C overnight. Compound 5 was isolated by HPLC.
- the synthetic method C is shown by the reaction scheme (IN).
- Compounds 1, 2, 3, and 4 were consecutively prepared and isolated as described in Method A. About 1 equivalent of compound 4 was dissolved in substituted phenylarnine followed by adding about 2 equivalent of sulfamic acid. The mixture was heated at about 200°C overnight.
- Compound 5 was isolated by HPLC and was dissolved in dry CH 2 CI 2 . The mixture was cooled to about -78°C using a dry ice-acetone bath. About 2 equivalents of BBr 3 (IM solution in CH 2 C1 2 ) was added dropwise to the mixture at about -78°C under nitrogen atmosphere.
- a balloon filled with hydrogen was placed on the top of the vial.
- the mixture was stirred at room temperature for about 2 hours.
- Celite was used to remove the palladium and carbon.
- the crude product and about 200 mg (0.74 mmol) of l-[2-(4- bromo-phenoxy)-ethyl]-pyrrolidine were dissolved in 10 ml of toluene.
- About 17 mg (0.018 mmol) of Pd(dba) 3 , about 34 mg (0.054 mmol) of BINAP, and about 50 mg (0.226 mmol) of KOt-Bu were added to the solution.
- the mixture was kept at about 100°C for about 24 hours under argon.
- the crude product was purified by preparative HPLC.
- the reactants were flushed with argon and diluted with ethylene glycol dimethyl ether (6 mL), ethanol (1 mL) and DI water (1 mL).
- the reaction vessel was outfitted with condenser and refluxed for 18 hours.
- the reaction was cooled to ambient temperature and the crude product was filtered, diluted with ethyl acetate, and washed with brine.
- the brine layer was back extracted once with fresh ethyl acetate.
- the organic phases were combined and dried over sodium sulfate (Na 2 SO 4 ). Filtration was followed by evaporation and silica gel chromatography (2:3 EtOAc/hexanes) provided the desired product as a yellow powder (0.08 g, 74% yield).
- the reactants were flushed with argon, diluted with dioxane (6 mL) and outfitted with reflux condenser. The reaction was heated to reflux for 18 hours, filtered hot, diluted with ethyl acetate and washed with brine. The brine layer was back extracted once with fresh ethyl acetate. The organic phases were combined and dried over sodium sulfate (Na 2 SO 4 ). Filtration followed by evaporation provided crude product, whichwas dissolved in minimum amount of DCM and precipitated out with excess hexanes. Solids were filtered off and dried to yield a yellow powder (0.06 g, 91% yield).
- the reactants were flushed with argon and diluted with ethylene glycol dimethyl ether (20 mL), ethanol (5 mL) and DI water (5 mL).
- the reaction vessel was outfitted with condenser and refluxed for 4 hours.
- the reaction was filtered hot and diluted with ethyl acetate.
- the Organic layer was isolated and concentrated to a dark residue. This was dissolved in DMF (6 mL) and slowly diluted with water so as to precipitate out the product. Solids were filtered off and dried to yield an orange solid (1 g, 82% yield).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005231507A AU2005231507B2 (en) | 2004-04-08 | 2005-04-07 | Benzotriazine inhibitors of kinases |
EP05762774.7A EP1809614B1 (en) | 2004-04-08 | 2005-04-07 | Benzotriazine inhibitors of kinases |
NZ551027A NZ551027A (en) | 2004-04-08 | 2005-04-07 | Benzotriazine inhibitors of kinases |
CN200580018660.1A CN101426772B (zh) | 2004-04-08 | 2005-04-07 | 激酶的苯并三嗪抑制物 |
CA2567574A CA2567574C (en) | 2004-04-08 | 2005-04-07 | Benzotriazine inhibitors of kinases |
IL178908A IL178908A (en) | 2004-04-08 | 2006-10-26 | Benzotriazines kinase inhibitors |
HK08100766.4A HK1110578A1 (en) | 2004-04-08 | 2008-01-21 | Benzotriazine inhibitors of kinases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56123704P | 2004-04-08 | 2004-04-08 | |
US60/561,237 | 2004-04-08 | ||
US64343905P | 2005-01-12 | 2005-01-12 | |
US60/643,439 | 2005-01-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005096784A2 true WO2005096784A2 (en) | 2005-10-20 |
WO2005096784A3 WO2005096784A3 (en) | 2009-02-19 |
Family
ID=35125563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/012057 WO2005096784A2 (en) | 2004-04-08 | 2005-04-07 | Benzotriazine inhibitors of kinases |
Country Status (10)
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006131835A2 (en) * | 2005-02-01 | 2006-12-14 | Sentinel Oncology Limited | Heterocyclic triazines as hypoxic selective protein kinase inhibitors |
EP1799656A1 (en) * | 2004-08-25 | 2007-06-27 | Targegen, Inc. | Heterocyclic compounds and methods of use |
EP1893216A1 (en) * | 2005-06-08 | 2008-03-05 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
WO2010076238A1 (en) | 2008-12-29 | 2010-07-08 | Fovea Pharmaceuticals Sa | Substituted quinazoline compounds |
WO2010092041A1 (en) | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals Sa | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
US7858782B2 (en) | 2006-12-15 | 2010-12-28 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
WO2011161159A1 (en) | 2010-06-22 | 2011-12-29 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
JP2012528136A (ja) * | 2009-05-26 | 2012-11-12 | センティネル・オンコロジー・リミテッド | p70S6キナーゼの阻害剤としての置換ベンゾトリアジン類およびキノキサリン類 |
EP2543376A1 (en) * | 2004-04-08 | 2013-01-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
US8877924B2 (en) | 2009-06-09 | 2014-11-04 | NantBio Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
AU2009322346B2 (en) * | 2008-12-03 | 2015-07-02 | The Scripps Research Institute | Stem cell cultures |
US9078902B2 (en) | 2009-06-09 | 2015-07-14 | Nantbioscience, Inc. | Triazine derivatives and their therapeutical applications |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9527816B2 (en) | 2005-05-10 | 2016-12-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10246393B2 (en) | 2016-10-31 | 2019-04-02 | Tosoh Corporation | Method for producing aromatic compound |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
MXPA05003477A (es) * | 2002-10-03 | 2005-07-22 | Targegen Inc | Agentes vasculo-estaticos y metodos de uso de los mismos. |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
BR122021011788B1 (pt) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
KR20080074220A (ko) * | 2005-12-08 | 2008-08-12 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 키나아제 억제 활성을 갖는 비시클릭 화합물 |
WO2007127366A2 (en) * | 2006-04-25 | 2007-11-08 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
WO2010008411A1 (en) * | 2007-11-09 | 2010-01-21 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
WO2009137052A1 (en) * | 2008-05-05 | 2009-11-12 | Winthrop University Hospital | Method for improving cardiovascular risk profile of cox inhibitors |
EP2447256A1 (en) * | 2010-10-21 | 2012-05-02 | Laboratorios Lesvi, S.L. | Process for obtaining dronedarone |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
WO2016089208A2 (en) | 2014-12-04 | 2016-06-09 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents |
CN116410159B (zh) * | 2023-06-09 | 2023-08-22 | 济南国鼎医药科技有限公司 | 一种恩曲替尼中间体的制备方法及其应用 |
Family Cites Families (161)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2003199A (en) * | 1930-05-31 | 1935-05-28 | Johnson Frank James | Automatic coal stoker |
US2003149A (en) * | 1931-05-22 | 1935-05-28 | Autographic Register Co | Manifolding |
US2003065A (en) | 1931-06-20 | 1935-05-28 | John R Ditmars | Composition for coating sheets, fibrous stocks, and the like |
US2004102A (en) * | 1932-02-24 | 1935-06-11 | Daniel A Dickey | Hollow steel propeller construction |
US2004138A (en) * | 1932-11-30 | 1935-06-11 | Byers A M Co | Method of making wrought iron pipe |
US2002165A (en) * | 1933-07-08 | 1935-05-21 | Charles A Winslow | Air cleaner |
US2003187A (en) * | 1933-10-02 | 1935-05-28 | Frederick H Shaw | Automobile radio device |
US2003166A (en) * | 1933-10-26 | 1935-05-28 | Zancan Ottavio | Front drive for motor cars |
US2001051A (en) * | 1933-12-01 | 1935-05-14 | Angelina Mariani | Tamperproof meter box with cutout control and fuse drawer for electric meters |
US2004092A (en) * | 1933-12-15 | 1935-06-11 | John L Chaney | Device for indicating the temperature of liquids |
US2003060A (en) * | 1934-04-02 | 1935-05-28 | Ernest L Heckert | Thermostatic controlling device |
US2667486A (en) * | 1951-05-24 | 1954-01-26 | Research Corp | 2,4-diamino pteridine and derivatives |
IL26578A (en) | 1965-10-04 | 1970-11-30 | Merck & Co Inc | Pethridine compounds and their preparation |
DE2255947A1 (de) | 1972-11-15 | 1974-05-22 | Bayer Ag | Substituierte 3-amino-benzo-1,2,4triazin-di-n-oxide (1,4), verfahren zu ihrer herstellung sowie ihre verwendung als antimikrobielle mittel |
IE38778B1 (en) * | 1973-02-02 | 1978-05-24 | Ciba Geigy | New 1,2,4-benzotriazine derivatives |
FR2275461A1 (fr) | 1974-06-18 | 1976-01-16 | Labaz | Nouveaux stabilisants des polymeres et copolymeres du chlorure de vinyle |
AU535258B2 (en) * | 1979-08-31 | 1984-03-08 | Ici Australia Limited | Benzotriazines |
EP0059524A1 (en) | 1981-02-09 | 1982-09-08 | Smith and Nephew Associated Companies p.l.c. | Pharmaceutical composition containing aminopteridines or aminopyrimido(4,5-d)pyrimidines |
DE3205638A1 (de) | 1982-02-17 | 1983-08-25 | Hoechst Ag, 6230 Frankfurt | Trisubstituierte pyrimidin-5-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
US4490289A (en) * | 1982-09-16 | 1984-12-25 | Hoffmann-La Roche Inc. | Homogeneous human interleukin 2 |
US5624925A (en) * | 1986-09-25 | 1997-04-29 | Sri International | 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents |
JP2598100B2 (ja) | 1988-08-31 | 1997-04-09 | キヤノン株式会社 | 電子写真感光体 |
US5214059A (en) * | 1989-07-03 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Incorporated | 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders |
US5665543A (en) * | 1989-07-18 | 1997-09-09 | Oncogene Science, Inc. | Method of discovering chemicals capable of functioning as gene expression modulators |
US5776502A (en) * | 1989-07-18 | 1998-07-07 | Oncogene Science, Inc. | Methods of transcriptionally modulating gene expression |
JPH03127790A (ja) | 1989-10-11 | 1991-05-30 | Morishita Pharmaceut Co Ltd | N―(1h―テトラゾール―5―イル)―2―アニリノ―5―ピリミジンカルボキシアミド類及びその合成中間体 |
US5062685A (en) | 1989-10-11 | 1991-11-05 | Corning Incorporated | Coated optical fibers and cables and method |
GB9003553D0 (en) | 1990-02-16 | 1990-04-11 | Ici Plc | Herbicidal compositions |
JP2839106B2 (ja) | 1990-02-19 | 1998-12-16 | キヤノン株式会社 | 電子写真感光体 |
IE74711B1 (en) * | 1990-07-27 | 1997-07-30 | Ici Plc | Fungicides |
GB9016800D0 (en) * | 1990-07-31 | 1990-09-12 | Shell Int Research | Tetrahydropyrimidine derivatives |
DE4025891A1 (de) * | 1990-08-16 | 1992-02-20 | Bayer Ag | Pyrimidyl-substituierte acrylsaeureester |
JPH05345780A (ja) * | 1991-12-24 | 1993-12-27 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
HUT63941A (en) | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
US5482951A (en) | 1992-05-29 | 1996-01-09 | Kumiai Chemical Industry Co., Ltd. | Triazole derivatives as well as insecticide and acaricide |
US5763441A (en) | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
JPH0741461A (ja) | 1993-05-27 | 1995-02-10 | Eisai Co Ltd | スルホン酸エステル誘導体 |
JPH0782183A (ja) | 1993-09-09 | 1995-03-28 | Canon Inc | 液晶中間体化合物、液晶性化合物、高分子液晶化合物、高分子液晶共重合体化合物、それらの組成物、液晶素子および記録装置 |
DE4338704A1 (de) * | 1993-11-12 | 1995-05-18 | Hoechst Ag | Stabilisierte Oligonucleotide und deren Verwendung |
US5530000A (en) * | 1993-12-22 | 1996-06-25 | Ortho Pharmaceutical Corporation | Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors |
GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5597826A (en) * | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
DE19502912A1 (de) * | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
US6326487B1 (en) * | 1995-06-05 | 2001-12-04 | Aventis Pharma Deutschland Gmbh | 3 modified oligonucleotide derivatives |
US5827850A (en) | 1995-09-25 | 1998-10-27 | Sanofi Pharmaceuticals, Inc. | 1,2,4-benzotriazine oxides formulations |
WO1997011699A1 (en) | 1995-09-25 | 1997-04-03 | Sanofi Winthrop Inc. | 1,2,4-benzotriazine oxides formulations |
JPH09274290A (ja) | 1996-02-07 | 1997-10-21 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料用の現像液および処理方法 |
CA2246753C (en) * | 1996-02-23 | 2005-05-10 | Eli Lilly And Company | Non-peptidyl vasopressin v1a antagonists |
DE59707681D1 (de) * | 1996-10-28 | 2002-08-14 | Rolic Ag Zug | Vernetzbare, photoaktive Silanderivate |
EP1707631A3 (en) * | 1996-11-20 | 2006-12-27 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
JP3734903B2 (ja) * | 1996-11-21 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
JPH10153838A (ja) | 1996-11-22 | 1998-06-09 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
JP3720931B2 (ja) * | 1996-11-26 | 2005-11-30 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料の処理方法 |
US5935383A (en) * | 1996-12-04 | 1999-08-10 | Kimberly-Clark Worldwide, Inc. | Method for improved wet strength paper |
JPH10207019A (ja) | 1997-01-22 | 1998-08-07 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
JPH10213820A (ja) | 1997-01-31 | 1998-08-11 | Canon Inc | 液晶素子及び液晶装置 |
DE59807348D1 (de) * | 1997-02-05 | 2003-04-10 | Rolic Ag Zug | Photovernetzbare Silanderivate |
JPH10260512A (ja) | 1997-03-19 | 1998-09-29 | Fuji Photo Film Co Ltd | ハロゲン化銀感光材料の処理方法 |
US6070126A (en) * | 1997-06-13 | 2000-05-30 | William J. Kokolus | Immunobiologically-active linear peptides and method of identification |
US6235736B1 (en) | 1997-06-24 | 2001-05-22 | Nikken Chemicals Co., Ltd. | 3-anilino-2-cycloalkenone derivatives |
US6635626B1 (en) * | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US6685938B1 (en) * | 1998-05-29 | 2004-02-03 | The Scripps Research Institute | Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases |
US6136971A (en) * | 1998-07-17 | 2000-10-24 | Roche Colorado Corporation | Preparation of sulfonamides |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
FR2792314B1 (fr) | 1999-04-15 | 2001-06-01 | Adir | Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE60006541D1 (de) * | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
WO2001002359A1 (fr) * | 1999-07-01 | 2001-01-11 | Ajinomoto Co., Inc. | Composes heterocycliques et leurs applications en medecine |
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
BR0012697A (pt) | 1999-07-23 | 2002-04-09 | Shionogi & Co | Inibidores da diferenciação de th2 |
US6093838A (en) * | 1999-08-16 | 2000-07-25 | Allergan Sales, Inc. | Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
US6127382A (en) * | 1999-08-16 | 2000-10-03 | Allergan Sales, Inc. | Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
US6506769B2 (en) * | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
WO2001027105A1 (fr) | 1999-10-12 | 2001-04-19 | Takeda Chemical Industries, Ltd. | Composes de pyrimidine-5-carboxamide, procede de preparation et d'utilisation desdits composes |
US6638929B2 (en) * | 1999-12-29 | 2003-10-28 | Wyeth | Tricyclic protein kinase inhibitors |
US6153752A (en) * | 2000-01-28 | 2000-11-28 | Creanova, Inc. | Process for preparing heterocycles |
US20020165244A1 (en) * | 2000-01-31 | 2002-11-07 | Yuhong Zhou | Mucin synthesis inhibitors |
GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
AU2001245401A1 (en) * | 2000-03-01 | 2001-09-12 | Sumitomo Pharmaceuticals Company, Limited | Hydrazones and analogs as cholesterol lowering agents |
JP2001247411A (ja) | 2000-03-09 | 2001-09-11 | Tomono Agrica Co Ltd | 有害生物防除剤 |
US6608048B2 (en) * | 2000-03-28 | 2003-08-19 | Wyeth Holdings | Tricyclic protein kinase inhibitors |
KR20030009416A (ko) * | 2000-04-04 | 2003-01-29 | 시오노기세이야쿠가부시키가이샤 | 고지용성 약물을 함유하는 유성 조성물 |
US6471968B1 (en) * | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
DE10024622A1 (de) | 2000-05-18 | 2001-11-22 | Piesteritz Stickstoff | N-(2-Pyrimidinyl)(thio)phosphorsäuretriamide, Verfahren zu ihrer Herstellung und deren Verwendung als Mittel zur Regulierung bzw. Hemmung der enzymatischen Harnstoff-Hydrolyse |
US6875483B2 (en) | 2000-07-06 | 2005-04-05 | Fuji Photo Film Co., Ltd. | Liquid crystal composition comprising liquid crystal molecules and alignment promoter |
US6489328B2 (en) * | 2000-08-11 | 2002-12-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
JP2002221770A (ja) | 2001-01-24 | 2002-08-09 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料およびその処理方法 |
EP1401833A2 (fr) * | 2001-05-28 | 2004-03-31 | Aventis Pharma S.A. | Derives chimiques et leur application comme agent antitelomerase |
CA2449118A1 (en) * | 2001-05-29 | 2002-12-05 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
WO2003004492A1 (en) * | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
EP1453516A2 (de) * | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
ATE407678T1 (de) * | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
US20060292206A1 (en) * | 2001-11-26 | 2006-12-28 | Kim Steven W | Devices and methods for treatment of vascular aneurysms |
US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US20030166932A1 (en) * | 2002-01-04 | 2003-09-04 | Beard Richard L. | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
JP2005524668A (ja) * | 2002-03-01 | 2005-08-18 | スミスクライン ビーチャム コーポレーション | ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用 |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
JP4570955B2 (ja) | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
ES2337782T3 (es) | 2002-07-29 | 2010-04-29 | Rigel Pharmaceuticals, Inc. | Metodos para tratar o prevenir enfermedades autoinmunitarias con compuestos de 2,4-pirimidindiamina. |
CN100491374C (zh) * | 2002-08-02 | 2009-05-27 | Ab科学公司 | 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用 |
NZ538715A (en) * | 2002-08-14 | 2007-07-27 | Vertex Pharma | Protein kinase inhibitors and uses thereof |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
DE10240261A1 (de) | 2002-08-31 | 2004-03-11 | Clariant Gmbh | Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Halogen-Metall-Austauschreaktionen |
DE10240262A1 (de) * | 2002-08-31 | 2004-03-11 | Clariant Gmbh | Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Aryllithium-Basen |
MXPA05003477A (es) * | 2002-10-03 | 2005-07-22 | Targegen Inc | Agentes vasculo-estaticos y metodos de uso de los mismos. |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
WO2004032709A2 (en) | 2002-10-04 | 2004-04-22 | Caritas St.Elisabeth's Medical Center Of Boston, Inc. | Inhibition of src for treatment of reperfusion injury related to revascularization |
EP1551813A4 (en) | 2002-10-10 | 2007-07-11 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
US20040132732A1 (en) | 2002-10-21 | 2004-07-08 | Wei Han | Quinazolinones and derivatives thereof as factor Xa inhibitors |
AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
DE10250708A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
KR20050075430A (ko) | 2002-11-19 | 2005-07-20 | 메모리 파마슈티칼스 코포레이션 | 포스포디에스테라제 4 억제제 |
AU2003280188A1 (en) | 2002-12-06 | 2004-06-30 | Warner-Lambert Company Llc | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
JP3837670B2 (ja) | 2002-12-12 | 2006-10-25 | 富士通株式会社 | データ中継装置、連想メモリデバイス、および連想メモリデバイス利用情報検索方法 |
WO2004060376A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corpration | The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives |
JP2006518333A (ja) | 2002-12-20 | 2006-08-10 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
ATE412657T1 (de) | 2002-12-24 | 2008-11-15 | Astrazeneca Ab | Therapeutische quinazolin-derivate |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
NZ541902A (en) | 2003-02-07 | 2008-12-24 | Janssen Pharmaceutica Nv | Pyrimidine derivatives for the prevention of HIV infection |
DE602004015254D1 (de) | 2003-02-07 | 2008-09-04 | Janssen Pharmaceutica Nv | Hiv-inhibierende1,2,4-triazine |
US20040248850A1 (en) | 2003-02-11 | 2004-12-09 | Kemia, Inc. | Compounds for the treatment of HIV infection |
CL2004000306A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
JP5047613B2 (ja) | 2003-04-24 | 2012-10-10 | クーパーヴィジョン インターナショナル ホウルディング カンパニー リミテッド パートナーシップ | ヒドロゲルコンタクトレンズ及び包装システム及びそれらの製造方法 |
PL2287156T3 (pl) | 2003-08-15 | 2013-11-29 | Novartis Ag | 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego |
AU2004272288B2 (en) | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
SI2213661T1 (sl) | 2003-09-26 | 2011-11-30 | Exelixis Inc | c-Met modulatorji in postopki uporabe |
WO2005035541A1 (en) | 2003-10-07 | 2005-04-21 | Amedis Pharmaceuticals Ltd. | Silicon compounds and their use |
DE10356579A1 (de) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
WO2005070891A2 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc | Compounds and methods of use |
RU2006139258A (ru) | 2004-04-08 | 2008-05-20 | Таргеджен, Инк. (US) | Бензотриазиновые ингибиторы киназ |
WO2005108370A1 (ja) | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | ベンゼン化合物 |
EP1799656A4 (en) | 2004-08-25 | 2009-09-02 | Targegen Inc | HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
US7210697B2 (en) * | 2004-12-16 | 2007-05-01 | Tricam International, Inc. | Convertible handle |
RU2368602C2 (ru) | 2005-01-26 | 2009-09-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназ |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
EP1863794A2 (en) * | 2005-03-16 | 2007-12-12 | Targegen, Inc. | Pyrimidine compounds and methods of use |
US20070032493A1 (en) * | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
WO2006133411A1 (en) | 2005-06-08 | 2006-12-14 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
EP1940843A4 (en) | 2005-08-11 | 2010-09-15 | Ariad Pharma Inc | UNSATURATED HETEROCYCLIC DERIVATIVES |
TW200745066A (en) | 2005-09-16 | 2007-12-16 | Torrent Pharmaceuticals Ltd | Novel PTP1B inhibitors |
US20070072682A1 (en) * | 2005-09-29 | 2007-03-29 | Crawford James T Iii | Head to head electronic poker game assembly and method of operation |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
BR122021011788B1 (pt) * | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US20070149508A1 (en) * | 2005-11-02 | 2007-06-28 | Targegen, Inc. | Six membered heteroaromatic inhibitors targeting resistant kinase mutations |
WO2007127366A2 (en) | 2006-04-25 | 2007-11-08 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
WO2009026346A1 (en) | 2007-08-20 | 2009-02-26 | Targegen Inc. | Thiazolidine compounds, and methods of making and using same |
WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
WO2009055674A1 (en) | 2007-10-26 | 2009-04-30 | Targegen Inc. | Pyrrolopyrimidine alkynyl compounds and methods of making and using same |
US20110166149A1 (en) | 2008-02-08 | 2011-07-07 | Targegen Inc. | Pteridine derivatives for treating respiratory disease |
RU2011108563A (ru) | 2008-08-05 | 2012-09-10 | Таргеджен, Инк. (US) | Способы лечения талассемии |
-
2005
- 2005-04-07 RU RU2006139258/04A patent/RU2006139258A/ru not_active Application Discontinuation
- 2005-04-07 NZ NZ551027A patent/NZ551027A/en not_active IP Right Cessation
- 2005-04-07 WO PCT/US2005/012057 patent/WO2005096784A2/en active Application Filing
- 2005-04-07 EP EP05762774.7A patent/EP1809614B1/en not_active Not-in-force
- 2005-04-07 AU AU2005231507A patent/AU2005231507B2/en not_active Ceased
- 2005-04-07 US US11/102,405 patent/US7456176B2/en active Active
- 2005-04-07 EP EP12167912A patent/EP2543376A1/en not_active Withdrawn
- 2005-04-07 KR KR1020067023392A patent/KR20070011458A/ko not_active Application Discontinuation
- 2005-04-07 CA CA2567574A patent/CA2567574C/en not_active Expired - Fee Related
- 2005-04-07 NZ NZ588139A patent/NZ588139A/en not_active IP Right Cessation
-
2006
- 2006-10-26 IL IL178908A patent/IL178908A/en not_active IP Right Cessation
-
2008
- 2008-01-21 HK HK08100766.4A patent/HK1110578A1/xx not_active IP Right Cessation
- 2008-09-09 US US12/207,019 patent/US20090275569A1/en not_active Abandoned
-
2010
- 2010-12-28 US US12/980,235 patent/US8481536B2/en active Active
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP1809614A4 |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2543376A1 (en) * | 2004-04-08 | 2013-01-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
US8481536B2 (en) | 2004-04-08 | 2013-07-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
US8372971B2 (en) | 2004-08-25 | 2013-02-12 | Targegen, Inc. | Heterocyclic compounds and methods of use |
EP1799656A1 (en) * | 2004-08-25 | 2007-06-27 | Targegen, Inc. | Heterocyclic compounds and methods of use |
EP1799656A4 (en) * | 2004-08-25 | 2009-09-02 | Targegen Inc | HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
AU2005276974B2 (en) * | 2004-08-25 | 2012-08-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
EP2532653A1 (en) * | 2004-08-25 | 2012-12-12 | Targegen, Inc. | Benzo[1,2,4]triazines as protein kinase modulators |
US8084618B2 (en) | 2004-08-25 | 2011-12-27 | Targegen, Inc. | Heterocyclic compounds and methods of use |
WO2006131835A3 (en) * | 2005-02-01 | 2007-05-10 | Sentinel Oncology Ltd | Heterocyclic triazines as hypoxic selective protein kinase inhibitors |
WO2006131835A2 (en) * | 2005-02-01 | 2006-12-14 | Sentinel Oncology Limited | Heterocyclic triazines as hypoxic selective protein kinase inhibitors |
US10010536B2 (en) | 2005-05-10 | 2018-07-03 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US9527816B2 (en) | 2005-05-10 | 2016-12-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
EP1893216A4 (en) * | 2005-06-08 | 2012-08-08 | Targegen Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES |
EP1893216A1 (en) * | 2005-06-08 | 2008-03-05 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
US7858782B2 (en) | 2006-12-15 | 2010-12-28 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
EP2923703A1 (en) | 2006-12-15 | 2015-09-30 | Abraxis BioScience, Inc. | Triazine derivatives and their therapeutical applications |
EP2425840A1 (en) | 2006-12-15 | 2012-03-07 | Abraxis BioScience, Inc. | Triazine derivatives and their therapeutical applications |
US8580786B2 (en) | 2006-12-15 | 2013-11-12 | Nant Holdings Ip, Llc | Triazine derivatives and their therapeutical applications |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9290450B2 (en) | 2008-06-03 | 2016-03-22 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
USRE47142E1 (en) | 2008-06-03 | 2018-11-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US10975352B2 (en) | 2008-12-03 | 2021-04-13 | The Scripps Research Institute | Methods of enhancing cell survival of stem cells |
US9896655B2 (en) | 2008-12-03 | 2018-02-20 | The Scripps Research Institute | Methods of enhancing cell survival of stem cells |
AU2009322346B2 (en) * | 2008-12-03 | 2015-07-02 | The Scripps Research Institute | Stem cell cultures |
US10351822B2 (en) | 2008-12-03 | 2019-07-16 | The Scripps Research Institute | Methods of enhancing cell survival of stem cells |
US9340525B2 (en) | 2008-12-03 | 2016-05-17 | The Scripps Research Institute | Stem cell cultures |
WO2010076238A1 (en) | 2008-12-29 | 2010-07-08 | Fovea Pharmaceuticals Sa | Substituted quinazoline compounds |
WO2010092041A1 (en) | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals Sa | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
US8716473B2 (en) | 2009-05-26 | 2014-05-06 | Sentinel Oncology Limited | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase |
JP2012528136A (ja) * | 2009-05-26 | 2012-11-12 | センティネル・オンコロジー・リミテッド | p70S6キナーゼの阻害剤としての置換ベンゾトリアジン類およびキノキサリン類 |
US8877924B2 (en) | 2009-06-09 | 2014-11-04 | NantBio Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
US9409903B2 (en) | 2009-06-09 | 2016-08-09 | Nantbioscience, Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
US9078902B2 (en) | 2009-06-09 | 2015-07-14 | Nantbioscience, Inc. | Triazine derivatives and their therapeutical applications |
WO2011161159A1 (en) | 2010-06-22 | 2011-12-29 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
US9675593B2 (en) | 2012-10-02 | 2017-06-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10376497B2 (en) | 2012-10-02 | 2019-08-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10898474B2 (en) | 2012-10-02 | 2021-01-26 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10544161B2 (en) | 2014-04-02 | 2020-01-28 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10246393B2 (en) | 2016-10-31 | 2019-04-02 | Tosoh Corporation | Method for producing aromatic compound |
Also Published As
Publication number | Publication date |
---|---|
US20090275569A1 (en) | 2009-11-05 |
KR20070011458A (ko) | 2007-01-24 |
AU2005231507B2 (en) | 2012-03-01 |
US20110294796A1 (en) | 2011-12-01 |
EP1809614B1 (en) | 2014-05-07 |
EP1809614A4 (en) | 2010-02-17 |
CA2567574C (en) | 2013-01-08 |
IL178908A0 (en) | 2011-08-01 |
US8481536B2 (en) | 2013-07-09 |
WO2005096784A3 (en) | 2009-02-19 |
EP2543376A1 (en) | 2013-01-09 |
NZ551027A (en) | 2011-01-28 |
NZ588139A (en) | 2012-02-24 |
HK1110578A1 (en) | 2008-07-18 |
US20050245524A1 (en) | 2005-11-03 |
AU2005231507A1 (en) | 2005-10-20 |
US7456176B2 (en) | 2008-11-25 |
EP1809614A2 (en) | 2007-07-25 |
CA2567574A1 (en) | 2005-10-20 |
IL178908A (en) | 2015-09-24 |
RU2006139258A (ru) | 2008-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005231507B2 (en) | Benzotriazine inhibitors of kinases | |
DK1951684T3 (en) | BIARYLMETAPYRIMIDIN kinase inhibitors | |
AU2003282726B2 (en) | Vasculostatic agents and methods of use thereof | |
AU2006227628A1 (en) | Pyrimidine compounds and methods of use | |
WO2007056075A2 (en) | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | |
JP6175139B2 (ja) | 新規トリアジン化合物 | |
CN111566100B (zh) | 嘧啶类化合物、其制备方法及其医药用途 | |
CN101426772B (zh) | 激酶的苯并三嗪抑制物 | |
AU2012202928A1 (en) | Benzotriazine inhibitors of kinases | |
EP4382514A1 (en) | Pyrimidine derivative, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 178908 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005231507 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 551027 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006502199 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200609267 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006139258 Country of ref document: RU Ref document number: 1020067023392 Country of ref document: KR Ref document number: 6617/DELNP/2006 Country of ref document: IN Ref document number: 2005762774 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2567574 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2005231507 Country of ref document: AU Date of ref document: 20050407 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005231507 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580018660.1 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067023392 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005762774 Country of ref document: EP |